Today’s common bioprocessing technologies do not efficiently develop complex biologics like cell and gene therapy and mRNA products. The at-line monitoring, off-line analytics, and legacy control ...

The starting material for virtually all pharmaceuticals and biologics is a synthetic or chemical. Human plasma-derived therapies are one of the few exceptions. A number of fragile proteins can be ...

In smart manufacturing, timely and accurate data flow is critical. Manufacturers seek to monitor every step in their process to ensure optimal results. However, significant challenges include ...